VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 03/23/18 -- Novoheart Holdings Inc. ("Novoheart" or the "Company") (TSX VENTURE: NVH)(FRANKFURT: 3NH) announced today that it has granted incentive stock options to purchase an aggregate of 693,522 common shares of the Company (the "Options") to certain directors and employees of the Company. The Options have an exercise price of $0.50 per common share. 520,000 of the Options expire on September 27, 2022 and vest 40% on September 27, 2018 and 30% on each of September 27, 2019 and 2020. The balance of the Options expire on February 23, 2023 and vest 40% on the first anniversary of the grant date and 30% on each of the second and third anniversaries of the grant date.
The Option grants are subject to the acceptance of the TSX Venture Exchange.
About Novoheart:
Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics. Also known as 'human heart-in-a-jar', Novoheart's bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation; statements about the Company's future plans, its goals and expectations, and the potential applications of its MyHeart? platform are forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the management discussion and analysis section of Novoheart Holdings Inc.'s interim and most recent annual financial statement or other reports and filings with the TSX Venture Exchange and applicable Canadian securities regulators. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements.
Contacts:
Novoheart
Ronald Li
CEO
info@novoheart.com
Virtus Advisory Group
Babak Pedram
Investor Relations
416-995-8651
bpedram@virtusadvisory.com
For media enquiries or interviews, please contact:
Josh Stanbury
Media Relations
416-628-7441
media@novoheart.com
